{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:28:40Z","timestamp":1767205720545,"version":"build-2238731810"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple sclerosis (MS) is characterized by chronic inflammation driven by central nervous system (CNS)-resident immune cells such as microglia, especially during the progressive phase of the disease. The P2X7 receptor (P2X7R), a risk protein for MS, is ubiquitously expressed on immune cells. AFC-5128, a CNS-penetrating small molecule inhibitor of P2X7R, is a promising agent for the treatment of autoimmune diseases such as MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>In vitro<\/jats:italic>\n                      , the effects on the calcium influx of primary murine microglia were assessed via Fluo-4 calcium imaging.\n                      <jats:italic>In vivo<\/jats:italic>\n                      , MOG\n                      <jats:sub>35-55<\/jats:sub>\n                      immunized C57BL\/6 mice were treated with AFC-5128, fingolimod (FTY) or vehicle in different treatment paradigms. The mice were scored daily. Microglial marker expression, immune cell phenotyping and serum cytokine analyses were performed via flow cytometry. Immune cell infiltration, demyelination and Iba1\n                      <jats:sup>+<\/jats:sup>\n                      \/CD3\n                      <jats:sup>+<\/jats:sup>\n                      cells were detected in spinal cord cross-sections. The effects of MOG\n                      <jats:sub>35-55<\/jats:sub>\n                      T-cell restimulation were assessed\n                      <jats:italic>in vitro<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>In vitro<\/jats:italic>\n                      , treatment of primary microglia with 10 \u00b5M AFC-5128 reduced the influx of calcium following ATP stimulation (p&amp;lt;0.0001).\n                      <jats:italic>In vivo<\/jats:italic>\n                      , treatment of mice with AFC-5128 led to a reduction in overall EAE scores in acute and chronic EAE, with the best effects using 200 mg\/kg body weight AFC-5128 (p&amp;lt;0.0001). Peripheral immune cell subsets (B cells, T cells and macrophages) and serum cytokine levels of chronic EAE mice treated in a therapeutic paradigm were not affected. While the expression of homeostasis markers of microglia in AFC-5128-treated mice was not affected, there was a trend toward lower expression of phagocytosis-associated markers. Late therapeutic treatment with AFC-5128 had only mild effects on chronic EAE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The treatment of EAE mice with AFC-5128 improved acute and chronic EAE in different treatment paradigms, with positive effects on histological markers and slight modulation of microglial marker expression. Mechanistically, calcium influx of microglia was reduced following AFC-5128 treatment, which implies the ability of AFC-5128 to stabilize calcium homeostasis. Therefore, therapeutic inhibition of P2X7R via AFC-5128 has the potential for translation into a treatment of both relapsing and progressive forms of multiple sclerosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1554999","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:12:16Z","timestamp":1744762336000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm"],"prefix":"10.3389","volume":"16","author":[{"given":"Robert","family":"Hoffrogge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Karachunskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neele","family":"Heitmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Haupeltshofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiomara","family":"Pedreiturria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Kl\u00f6ster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verian","family":"Bader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstanze F.","family":"Winklhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hamacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert","family":"Klebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Dinkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Faissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.14","article-title":"Multiple sclerosis-a quiet revolution","volume":"11","author":"Ransohoff","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0035-2","article-title":"Progressive multiple sclerosis: from pathophysiology to therapeutic strategies","volume":"18","author":"Faissner","year":"2019","journal-title":"Nat Rev Drug discovery."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/112.1.133","article-title":"The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0488-6","article-title":"Efficacy and safety of the newer multiple sclerosis drugs approved since 2010","volume":"32","author":"Faissner","year":"2018","journal-title":"CNS Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1756286419878323","DOI":"10.1177\/1756286419878323","article-title":"Progressive multiple sclerosis: latest therapeutic developments and future directions","volume":"12","author":"Faissner","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00624-x","article-title":"The role of glial cells in multiple sclerosis disease progression","volume":"18","author":"Healy","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh641","article-title":"Cortical demyelination and diffuse white matter injury in multiple sclerosis","volume":"128","author":"Kutzelnigg","year":"2005","journal-title":"Brain"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.06.009","article-title":"P2X7 receptor: A potential therapeutic target for autoimmune diseases","volume":"18","author":"Cao","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000222","article-title":"The expression of P2X7 receptor on th1, th17, and regulatory T cells in patients with systemic lupus erythematosus or rheumatoid arthritis and its correlations with active disease","volume":"205","author":"Li","year":"2020","journal-title":"J Immunol (Baltimore Md: 1950)."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01529","article-title":"Modulation of P2X7 receptor during inflammation in multiple sclerosis","volume":"8","author":"Amadio","year":"2017","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5512-08.2009","article-title":"The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore","volume":"29","author":"Monif","year":"2009","journal-title":"J Neurosci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"106601","DOI":"10.1016\/j.nbd.2024.106601","article-title":"Increased concentrations of P2X7R in oligodendrocyte derived extracellular vesicles of Multiple sclerosis patients","volume":"199","author":"Agliardi","year":"2024","journal-title":"Neurobiol disease."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20110","article-title":"The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes","volume":"49","author":"Narcisse","year":"2005","journal-title":"Glia."},{"key":"B15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2377-6-12","article-title":"COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord","volume":"6","author":"Yiangou","year":"2006","journal-title":"BMC neurology."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0579-07.2007","article-title":"P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis","volume":"27","author":"Matute","year":"2007","journal-title":"J Neurosci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12974-017-1034-z","article-title":"Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis","volume":"14","author":"Beaino","year":"2017","journal-title":"J neuroinflammation."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/humu.2017.38.issue-6","article-title":"Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis","volume":"38","author":"Sadovnick","year":"2017","journal-title":"Hum Mutat"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315381","article-title":"Two single nucleotide polymorphisms in the purinergic receptor P2X7 gene are associated with disease severity in multiple sclerosis","volume":"23","author":"Guerini","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.1989","article-title":"Protocol for primary microglial culture preparation","volume":"6","author":"Lian","year":"2016","journal-title":"Bio Protoc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656941","article-title":"Clozapine regulates microglia and is effective in chronic experimental autoimmune encephalomyelitis","volume":"12","author":"Ceylan","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.759389","article-title":"Progressive retinal and optic nerve damage in a mouse model of spontaneous opticospinal encephalomyelitis","volume":"12","author":"Petrikowski","year":"2022","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"101670","DOI":"10.1016\/j.xpro.2022.101670","article-title":"Using mechanical homogenization to isolate microglia from mouse brain tissue to preserve transcriptomic integrity","volume":"3","author":"Herron","year":"2022","journal-title":"STAR Protoc"},{"key":"B24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-62703-520-0_3","article-title":"Microglia isolation from adult mouse brain","volume":"1041","author":"Lee","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11302-021-09796-5","article-title":"Involvement of P2X7 receptors in chronic pain disorders","volume":"18","author":"Ren","year":"2022","journal-title":"Purinergic Signal"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00015.2002","article-title":"Molecular physiology of P2X receptors","volume":"82","author":"North","year":"2002","journal-title":"Physiol Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202003.0288.v1","article-title":"Regulation of microglial functions by purinergic mechanisms in the healthy and diseased CNS","volume":"9","author":"Illes","year":"2020","journal-title":"Cells."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2004.04.015","article-title":"Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice","volume":"153","author":"Webb","year":"2004","journal-title":"J neuroimmunology."},{"key":"B29","article-title":"FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration","volume":"2","author":"Kataoka","year":"2005","journal-title":"Cell Mol Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939838","article-title":"Oxidized ATP inhibits T-cell-mediated autoimmunity","volume":"40","author":"Lang","year":"2010","journal-title":"Eur J Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12974-024-03057-z","article-title":"P2X7 receptor antagonists modulate experimental autoimmune neuritis via regulation of NLRP3 inflammasome activation and Th17 and Th1 cell differentiation","volume":"21","author":"Xie","year":"2024","journal-title":"J neuroinflammation."},{"key":"B32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12974-018-1205-6","article-title":"Serum amyloid A primes microglia for ATP-dependent interleukin-1\u03b2 release","volume":"15","author":"Facci","year":"2018","journal-title":"J neuroinflammation."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-018-0528-3","article-title":"Early P2X7R-dependent activation of microglia during the asymptomatic phase of autoimmune encephalomyelitis","volume":"27","author":"Grygorowicz","year":"2019","journal-title":"Inflammopharmacology."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00718-z","article-title":"The immunology of multiple sclerosis","volume":"22","author":"Attfield","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00948-8","article-title":"Skin and gut imprinted helper T cell subsets exhibit distinct functional phenotypes in central nervous system autoimmunity","volume":"22","author":"Hiltensperger","year":"2021","journal-title":"Nat Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.5.3115","article-title":"Exacerbation of experimental autoimmune encephalomyelitis in P2X7R-\/- mice: evidence for loss of apoptotic activity in lymphocytes","volume":"176","author":"Chen","year":"2006","journal-title":"J Immunol (Baltimore Md: 1950)."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx113","article-title":"Loss of \u2018homeostatic\u2019 microglia and patterns of their activation in active multiple sclerosis","volume":"140","author":"Zrzavy","year":"2017","journal-title":"Brain."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2022.06.023","article-title":"Microglia in multiple sclerosis: Protectors turn destroyers","volume":"110","author":"Yong","year":"2022","journal-title":"Neuron."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051663","article-title":"Strategies for neuroprotection in multiple sclerosis and the role of calcium","volume":"21","author":"Enders","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18020353","article-title":"Excitotoxins, mitochondrial and redox disturbances in multiple sclerosis","volume":"18","author":"Rajda","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/nen.0b013e31812571b0","article-title":"Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage","volume":"66","author":"Vercellino","year":"2007","journal-title":"J neuropathology Exp neurology."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2015.04.042","article-title":"AMPA receptor activation causes preferential mitochondrial Ca\u00b2+ load and oxidative stress in motor neurons","volume":"1616","author":"Joshi","year":"2015","journal-title":"Brain Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000660","article-title":"Pharmacologic characterizations of a P2X7 receptor-specific radioligand, [11C]GSK1482160 for neuroinflammatory response","volume":"38","author":"Han","year":"2017","journal-title":"Nucl Med Commun"},{"key":"B44","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12974-020-01962-7","article-title":"PET imaging of P2X(7)R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [(11)C]SMW139","volume":"17","author":"Beaino","year":"2020","journal-title":"J neuroinflammation."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet (London England)."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156468","article-title":"Critical evaluation of P2X7 receptor antagonists in selected seizure models","volume":"11","author":"Fischer","year":"2016","journal-title":"PloS One"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1111\/bph.v179.12","article-title":"Increased expression of the ATP-gated P2X7 receptor reduces responsiveness to anti-convulsants during status epilepticus in mice","volume":"179","author":"Beamer","year":"2022","journal-title":"Br J Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1631-4","article-title":"Multiple sclerosis: experimental models and reality","volume":"113","author":"Lassmann","year":"2016","journal-title":"Acta neuropathologica."}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1652299","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1554999\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T10:59:39Z","timestamp":1753354779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1554999\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2025.1554999"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1554999","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"1554999"}}